1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Global Neurodegenerative Diseases Market 2015-2019

Global Neurodegenerative Diseases Market 2015-2019

  • May 2015
  • -
  • Infiniti Research Limited
  • -
  • 168 pages

About neurodegenerative diseases
According to the EU JPND, neurodegenerative diseases refer to conditions that involve the neurons in the brain. These conditions can affect balance, movement, speech, and respiratory and cardiac functions. They can be inherited or be of unknown etiology. Neurodegenerative diseases are incurable and are severely debilitating. They result in progressive degeneration of nerve cells, causing them to die eventually. These diseases cause ataxia and dementia in people, which can have a serious impact on the mental health of patients. Some examples of neurodegenerative diseases are Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and epilepsy. Huntington’s disease and amyotrophic lateral sclerosis are rare diseases, unlike Alzheimer’s disease and Parkinson’s disease which have a high degree of prevalence.
Technavio's analysts forecast the global neurodegenerative diseases market to grow at a CAGR of 4.77 percent over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global neurodegenerative diseases market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of neurodegenerative diseases. The market includes data from the sales of various drugs used in the treatment of:
• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Epilepsy
• Huntington's Disease
• Amyotrophic Lateral Sclerosis
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the global neurodegenerative diseases market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. In addition, late-stage pipeline molecules developed for the treatment of neurodegenerative diseases are discussed.
Technavio's report, Global Neurodegenerative Diseases Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC; it also covers the global neurodegenerative diseases market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key regions
• Americas
• APAC
• EMEA

Key vendors
• Biogen Idec
• Merck Serono
• Novartis
• Pfizer
• Teva Pharmaceutical Industries
• UCB
Other prominent vendors

• AB Science
• Abbvie
• Acorda Therapeutics
• Actavis
• Active Biotech
• Adamas Pharmaceuticals
• Akorn
• Archer Pharmaceuticals
• Astellas
• Auspex Pharmaceuticals
• Bayer
• Boehringer Ingelheim
• Covis
• Desitin Arzneimittel
• Eisai
• Eli Lilly
• Endo International
• F. Hoffmann-La Roche
• FORUM Pharmaceuticals
• GlaxoSmithKline
• Glenmark
• H. Lundbeck
• Ipsen
• Janssen Pharmaceuticals
• Kyowa Hakko Kirin
• Mitsubishi Tanabe
• MorphoSys
• Newron Pharmaceuticals
• Omeros
• Opexa
• Orion
• Otsuka Pharmaceutical
• Oxford BioMedica
• Palobiofarma
• Prana Biotechnology
• Raptor Pharmaceutical
• Sanofi
• Siena Biotech
• SOM Biotech
• STADA
• Takeda Pharmaceutical
• TauRx Pharmaceuticals
• US WorldMeds
• Valeant
• Zinfandel Pharmaceuticals
Market driver
• High unmet medical needs
• For a full, detailed list, view our report
Market challenge
• Generic erosion
• For a full, detailed list, view our report
Market trend
• Reformulation of marketed drugs
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Table Of Contents

Global Neurodegenerative Diseases Market 2015-2019
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Avonex/Rebif
04.1.2 Plegridy
04.1.3 Tecfidera
04.1.4 Tysabri
04.1.5 Comtan
04.1.6 Stalevo
04.1.7 Exelon/Exelon Patch
04.1.8 Extavia
04.1.9 Gilenya
04.1.10 Cerebyx
04.1.11 Dilantin-125
04.1.12 Lyrica
04.1.13 Neurontin
04.1.14 Zarontin
04.1.15 Azilect
04.1.16 Copaxone
04.1.17 Keppra/Keppra XR
04.1.18 Neupro
04.1.19 Vimpat
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Segmentation of Global Neurodegenerative Diseases Market by Type of Disease
09. Global Multiple Sclerosis Market
09.1 Multiple Sclerosis: Overview
09.1.1 About the Disease
09.1.2 Symptoms
09.1.3 Etiology
09.1.4 Epidemiology
09.1.5 Economic Burden
09.2 Market Overview
09.3 Market Size and Forecast
09.4 Multiple Sclerosis Market in US
09.4.1 Market Size and Forecast
10. Global Alzheimer's Disease Market
10.1 Alzheimer's Disease: Overview
10.1.1 About the Disease
10.1.2 Dementia
10.1.3 Epidemiology and Forecast
10.1.4 Types of Dementia
10.1.5 Global Burden
10.1.6 Etiology
10.1.7 Cost of Care
10.1.8 Alzheimer's Disease and Caregiving
10.2 Market Overview
10.3 Market Size and Forecast
11. Global Epilepsy Market
11.1 Epilepsy: Overview
11.1.1 About the Disease
11.1.2 Etiology
11.1.3 Types of Epilepsy
11.1.4 Symptoms
11.1.5 Epidemiology
11.1.6 Economic Burden
11.2 Market Overview
11.3 Market Size and Forecast
11.4 Epilepsy Market in US
11.4.1 Market Size and Forecast
11.5 Epilepsy Market in Europe
11.5.1 Market Size and Forecast
11.6 Epilepsy Market in Japan
11.6.1 Market Size and Forecast
12. Global Parkinson's Disease Market
12.1 Parkinson's Disease: Overview
12.1.1 About the Disease
12.1.2 Symptoms
12.1.3 Etiology
12.1.4 Epidemiology
12.1.5 Economic Burden
12.2 Market Overview
12.3 Market Size and Forecast
13. Global Huntington's Disease Market
13.1 Huntington's Disease: Overview
13.1.1 About the Disease
13.1.2 Symptoms
13.1.3 Etiology
13.1.4 Prevalence of Huntington's Disease
13.1.5 Pipeline Portfolio
13.1.6 Economic Burden
13.2 Market Overview
13.3 Market Size and Forecast
14. Global Amyotrophic Lateral Sclerosis Market
14.1 Amyotrophic Lateral Sclerosis: Overview
14.1.1 About the Disease
14.1.2 Types of Amyotrophic Lateral Sclerosis
14.1.3 Etiology and Pathophysiology
14.1.4 Symptoms
14.1.5 Epidemiology
14.1.6 Diagnosis
14.1.7 Pipeline Portfolio
14.2 Market Overview
14.3 Market Size and Forecast
15. Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule
15.1 Biologics
15.2 Small Molecules
16. Segmentation of Global Neurodegenerative Diseases Market by Route of Administration
16.1 Oral
16.2 Parenteral
16.3 Topical
17. Geographical Segmentation
18. Buying Criteria
19. Market Growth Drivers
20. Drivers and their Impact
21. Market Challenges
22. Impact of Drivers and Challenges
23. Market Trends
24. Trends and their Impact
25. Vendor Landscape
25.1 Competitive Scenario
25.1.1 Key News
25.1.2 Mergers and Acquisitions
25.2 Market Share Analysis 2014
25.2.1 Competitive Assessment of Major Drugs
25.2.2 Biogen Idec
25.2.3 Pfizer
25.2.4 Teva Pharmaceutical
25.2.5 Novartis
25.2.6 Merck Serono
25.2.7 UCB
25.3 Other and Potential Future Prominent Vendors
26. Key Vendor Analysis
26.1 Biogen Idec
26.1.1 Key Facts
26.1.2 Business Overview
26.1.3 Business Segmentation by Revenue 2013
26.1.4 Geographical Segmentation by Revenue 2013
26.1.5 Business Strategy
26.1.6 Key Developments
26.1.7 SWOT Analysis
26.2 Merck Serono
26.2.1 Key Facts
26.2.2 Business Overview
26.2.3 Geographical Segmentation by Revenue 2013
26.2.4 Business Strategy
26.2.5 Recent Developments
26.2.6 SWOT Analysis
26.3 Novartis
26.3.1 Key Facts
26.3.2 Business Description
26.3.3 Business Segmentation
26.3.4 Revenue by Business Segmentation
26.3.5 Revenue Comparison 2012 and 2013
26.3.6 Sales by Geography
26.3.7 Business Strategy
26.3.8 Key Developments
26.3.9 SWOT Analysis
26.4 Pfizer
26.4.1 Key Facts
26.4.2 Business Overview
26.4.3 Business Segmentation by Revenue 2013
26.4.4 Business Segmentation by Revenue 2012 and 2013
26.4.5 Geographical Segmentation by Revenue
26.4.6 Business Strategy
26.4.7 Key Developments
26.4.8 SWOT Analysis
26.5 Teva Pharmaceutical
26.5.1 Key Facts
26.5.2 Business Overview
26.5.3 Business Segmentation
26.5.4 Business Segmentation by Revenue 2013
26.5.5 Business Segmentation by Revenue 2012 and 2013
26.5.6 Sales by Geography
26.5.7 Business Strategy
26.5.8 Key Developments
26.5.9 SWOT Analysis
26.6 UCB
26.6.1 Key Facts
26.6.2 Business Overview
26.6.3 Product Segmentation by Revenue 2013
26.6.4 Product Segmentation by Revenue 2012 and 2013
26.6.5 Geographical Segmentation by Revenue 2013
26.6.6 Business Strategy
26.6.7 Recent Developments
26.6.8 SWOT Analysis
27. Other Reports in this Series


List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Neurodegenerative Diseases Market 2014-2019 ($ million)
Exhibit 3: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease
Exhibit 4: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease 2014
Exhibit 5: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease 2019
Exhibit 6: Etiology of Multiple Sclerosis
Exhibit 7: Global Multiple Sclerosis Market 2014-2019 ($ million)
Exhibit 8: Multiple Sclerosis Market in US 2014-2019 ($ million)
Exhibit 9: Prevalence of Dementia by Geography 2013, 2030, and 2050 (million)
Exhibit 10: Prevalence of Dementia by Geography 2013-2018 (millions)
Exhibit 11: Types of Dementia and Associated Symptoms
Exhibit 12: Types of Dementia by Prevalence 2013
Exhibit 13: Segmentation of Economic Burden of Alzheimer's Disease and Other Dementias by Geography 2013
Exhibit 14: Average Cost of Care for Americans Aged 65 and Above with Alzheimer's Disease and Other Dementias 2013
Exhibit 15: Distribution of Alzheimer's Caregivers by Age 2013
Exhibit 16: Projected Prevalence of Dependence 2010 and 2030
Exhibit 17: Global Alzheimer's Disease Market 2014-2019 ($ million)
Exhibit 18: Global Epilepsy Market 2014-2019 ($ million)
Exhibit 19: Epilepsy Market in US 2014-2019 ($ million)
Exhibit 20: Epilepsy Market in Europe 2014-2019 ($ million)
Exhibit 21: Epilepsy Market in Japan 2014-2019 ($ million)
Exhibit 22: Global Parkinson's Disease Market 2014-2019 ($ million)
Exhibit 23: Segmentation of Global Parkinson's Disease Market by Country 2014
Exhibit 24: Snapshot of Disease
Exhibit 25: Prevalence of Huntington's Disease by Geography 2013
Exhibit 26: Huntington's Disease: Pipeline Portfolio
Exhibit 27: Global Huntington's Disease Market 2014-2019 ($ million)
Exhibit 28: Snapshot of Disease
Exhibit 29: Amyotrophic Lateral Sclerosis: Pipeline Portfolio
Exhibit 30: Global Amyotrophic Lateral Sclerosis Market 2014-2019 ($ million)
Exhibit 31: Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule
Exhibit 32: Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule 2014
Exhibit 33: Segmentation of Global Neurodegenerative Diseases Market by Route of Administration
Exhibit 34: Segmentation of Global Neurodegenerative Diseases Market by Route of Administration 2014
Exhibit 35: Segmentation of Global Neurodegenerative Diseases Market by Geography 2014
Exhibit 36: Global Neurodegenerative Diseases Market Share Analysis 2014
Exhibit 37: Major Drugs for Neurodegenerative Diseases by Revenue 2014 ($ million)
Exhibit 38: YoY Revenue of Major Drugs for Neurodegenerative Diseases 2011-2014 ($ million)
Exhibit 39: Revenue Share of Major Drugs for Neurodegenerative Diseases 2011-2014
Exhibit 40: Biogen Idec: Global Revenue of Products 2011-2014 ($ million)
Exhibit 41: Biogen Idec: YoY Global Revenue of Avonex 2011-2014 ($ million)
Exhibit 42: Biogen Idec: Revenue of Avonex in US 2011-2014 ($ million)
Exhibit 43: Biogen Idec: Revenue of Avonex in ROW 2011-2014 ($ million)
Exhibit 44: Biogen Idec: YoY Global Revenue of Tysabri 2011-2014 ($ million)
Exhibit 45: Biogen Idec: Revenue of Tysabri in US 2011-2014 ($ million)
Exhibit 46: Biogen Idec: Revenue of Tysabri in ROW 2011-2014 ($ million)
Exhibit 47: Biogen Idec: YoY Global Revenue of Fampyra 2011-2014 ($ million)
Exhibit 48: Biogen Idec: Revenue of Plegridy in US and ROW 2014 ($ million)
Exhibit 49: Biogen Idec: Revenue of Tecfidera in US and ROW 2013 and 2014 ($ million)
Exhibit 50: Pfizer: YoY Global Revenue of Lyrica 2011-2014 ($ million)
Exhibit 51: Pfizer: YoY Global Revenue of Neurontin 2011-2013 ($ million)
Exhibit 52: Teva Pharmaceutical: YoY Global Revenue of Copaxone 2011-2014 ($ million)
Exhibit 53: Teva Pharmaceutical: Quarterly Revenue of Copaxone 2011-2014 ($ million)
Exhibit 54: Teva Pharmaceutical: YoY Global Revenue of Azilect 2011-2014 ($ million)
Exhibit 55: Teva Pharmaceutical: Quarterly Revenue of Azilect 2011-2014 ($ million)
Exhibit 56: Novartis: YoY Global Revenue of Gilenya 2011-2014 ($ million)
Exhibit 57: Novartis: Revenue of Gilenya in US and ROW 2011-2013 ($ million)
Exhibit 58: Novartis: YoY Global Revenue of Extavia 2011-2014 ($ million)
Exhibit 59: Novartis: YoY Global Revenue of Comtan/Stalevo 2011-2014 ($ million)
Exhibit 60: Novartis: Revenue of Comtan/Stalevo in US and ROW 2011-2013 ($ million)
Exhibit 61: Novartis: YoY Global Revenue of Exelon/Exelon Patch 2011-2014 ($ million)
Exhibit 62: Novartis: Revenue of Exelon/Exelon Patch in US and ROW 2011-2013 ($ million)
Exhibit 63: Merck Serono: YoY Global Revenue of Rebif 2011-2014 ($ million)
Exhibit 64: Merck Serono: Revenue of Rebif in North America 2011-2014 ($ million)
Exhibit 65: Merck Serono: Revenue of Rebif in Europe 2011-2014 ($ million)
Exhibit 66: Merck Serono: Revenue Share of Rebif by Region 2012-2014
Exhibit 67: UCB: YoY Global Revenue of Vimpat 2011-2014 ($ million)
Exhibit 68: UCB: YoY Revenue of Vimpat in Europe 2011-2014 ($ million)
Exhibit 69: UCB: YoY Revenue of Vimpat in North America 2011-2014 ($ million)
Exhibit 70: UCB: YoY Global Revenue of Keppra/Keppra XR 2011-2014 ($ million)
Exhibit 71: UCB: YoY Revenue of Keppra/Keppra XR in Europe 2011-2014 ($ million)
Exhibit 72: UCB: YoY Revenue of Keppra/Keppra XR in North America 2011-2014 ($ million)
Exhibit 73: UCB: YoY Global Revenue of Neupro 2011-2014 ($ million)
Exhibit 74: UCB: YoY Revenue of Neupro in Europe 2011-2014 ($ million)
Exhibit 75: UCB: YoY Revenue of Neupro in North America 2011-2014 ($ million)
Exhibit 76: Biogen Idec: Business Segmentation by Revenue 2013
Exhibit 77: Biogen Idec: Geographical Segmentation by Revenue 2013
Exhibit 78: Merck Serono: Geographical Segmentation by Revenue 2013
Exhibit 79: Novartis AG: Business Segmentation
Exhibit 80: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 81: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ million)
Exhibit 82: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 83: Pfizer: Business Segmentation by Revenue 2013
Exhibit 84: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 85: Pfizer: Geographical Segmentation by Revenue 2013
Exhibit 86: Teva Pharmaceutical Industries: Business Segmentation
Exhibit 87: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2013
Exhibit 88: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2012 and 2013 ($ million)
Exhibit 89: Teva Pharmaceutical Industries: Sales by Geography 2013
Exhibit 90: UCB: Product Segmentation by Revenue 2013
Exhibit 91: UCB: Product Segmentation by Revenue 2012 and 2013 ($ million)
Exhibit 92: UCB: Geographical Segmentation by Revenue 2013

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

Epilepsy  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Epilepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

Narcolepsy-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Narcolepsy - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...

Myasthenia Gravis-Market Insights, Epidemiology and Market Forecast-2023

Myasthenia Gravis-Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Myasthenia Gravis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.